Join Scrip editors Mandy Jackson and Mary Jo Laffler and Pink Sheet editor Sarah Karlin-Smith as they discuss the general mood at the recent BIO International Convention in Boston and around the current US economic and biopharma policy environment in general, along with other key topics at BIO including vaccines, deal and financing and the rise of China's innovation. https://insights.citeline.com/scrip/conferences/bio/post-bio-podcast-thoughts-from-the-frontlines-ID7TBPASUFG4HKFSH56TK44DUM/ https://insights.citeline.com/pink-sheet/conferences/bio/post-bio-podcast-thoughts-from-the-frontlines-VGDKPJ2QQRBV5B6TY36ROPKE4Q/ Time stamps (0:45) Economic and policy environment in the US (2:50) BIO leadership surprisingly open about the industry’s challenges, and willingness to call out Trump government (4:20) Most-favored nation policy proposal: storm in a teacup or existential threat (7:57) DTC sales: new opportunities to sidestep middlemen? GLP-1s leading the way (10:52) Impact of FDA staff cuts and changes on regulatory practices and policy, and on biopharma companies (16:47) Reaction of vaccine companies, health providers, insurers and other stakeholders to ACIP panel dismissal and policy uncertainty (22:27) Climate for biopharma dealmaking and financing; demand for assets (27:28) Advice for startups in challenging times (29:49) China’s biopharma industry in the ascendant (33:27) Rare diseases policy, regulation and industry focus (38:15) Priorities for BIO

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related